New York, NY -- (SBWIRE) -- 12/24/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Athersys, Inc (NASDAQ:ATHX), ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Genco Shipping & Trading Limited (NYSE:GNK), Gafisa SA (ADR) (NYSE:GFA)
Athersys, Inc (NASDAQ:ATHX) showed a volume of 1.74 million shares by the end of last trade whereas the average volume of the stock remained 1.06 million shares. The stock opened the session at $1.06 but then moved to $2.32. At that price, the stock showed a positive performance of 6.91%. Athersys Inc. is a biopharmaceutical company engaged in the field of regenerative medicine. During the year ended December 31, 2011 the Company is developing its platform product, MultiStem, a allogeneic stem cell product that has been evaluated in two completed Phase I clinical trials and as of December 31, 2011, is being evaluated in two ongoing Phase II clinical trials. The Company’s clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions.
Will ATHX Continue To Move Higher? Find Out Here
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) opened the session at $4.05 and closed the session at $4.27. The stock showed a positive performance of 6.75% in previous trading session. Traded with volume of 1.59 million shares in the prior session and the average volume of the stock remained 1.19 million shares. ZIOPHARM Oncology, Inc., is a biotechnology company. The Company employs gene expression and control technology to deliver deoxyribonucleic acid (DNA) for the treatment of cancer. The Company's technology employs Intrexon Corporation's RheoSwitch Therapeutic System to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. As of October 18, 2013, the technology was being evaluated in Phase II clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma.
For How Long ZIOP will fight for Profitability? Read This Trend Analysis report
Genco Shipping & Trading Limited (NYSE:GNK) opened the session at $1.90 and closed the session at $2.00. The stock showed a negative performance of -0.99% in previous trading session. Traded with volume of 1.41 million shares in the prior session and the average volume of the stock remained 1.95 million shares. The beta of the stock remained 1.55. Genco Shipping & Trading Limited (GS&T) transports iron ore, coal, grain, steel products and other drybulk cargoes along worldwide shipping routes through the ownership and operation of drybulk carrier vessels. As of December 31, 2012, GS&T’s fleet consisted of 53 drybulk carriers, including nine capesize, eight panamax, 17 supramax, six handymax and 13 handysize drybulk carriers, with an aggregate carrying capacity of approximately 3,810,000 deadweight tonnages.
Why Should Investors Buy GNK After the Recent Fall? Just Go Here and Find Out
Gafisa SA (ADR) (NYSE:GFA) the stock decreased -1.81% and finished the session at $3.26. Traded with volume of 1.30 million shares in the prior session and the average volume of the stock remained 1.61 million shares. The beta of the stock remained 2.55. Gafisa SA is a Brazil-based company engaged in the homebuilding and real estate operations. The Company is involved in the promotion, administration, purchase, sale and trade of real estate properties; provision of financing services to real estate customers; construction and provision of civil engineering services, and development and implementation of marketing strategies related to its own or third party real estate projects.
Will GFA Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)